IP Verse

Compositions And Methods For Lowering Levels Of High-Sensitivity (Hs-Crp) In A Subject - EP2800469

The patent EP2800469 was granted to Amarin Pharmaceuticals Ireland on Aug 25, 2021. The application was originally filed on Jan 7, 2013 under application number EP13733751A. The patent is currently recorded with a legal status of "Revoked".

EP2800469

AMARIN PHARMACEUTICALS IRELAND
Application Number
EP13733751A
Filing Date
Jan 7, 2013
Status
Revoked
Jan 27, 2023
Grant Date
Aug 25, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

COOKEMay 25, 2022ELKINGTON AND FIFEADMISSIBLE
ELKINGTON AND FIFEMay 23, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2011288171
INTERNATIONAL-SEARCH-REPORTUS2004048919
INTERNATIONAL-SEARCH-REPORTUS2005137253
INTERNATIONAL-SEARCH-REPORTUS2006172012
INTERNATIONAL-SEARCH-REPORTUS2010021555
INTERNATIONAL-SEARCH-REPORTUS2010278879
INTERNATIONAL-SEARCH-REPORTUS2011178105
INTERNATIONAL-SEARCH-REPORTUS2011288171
OPPOSITIONEP2022495
OPPOSITIONUS2004048919
OPPOSITIONUS2005137253
OPPOSITIONUS2006172012
OPPOSITIONUS2010021555
OPPOSITIONUS2010278879
OPPOSITIONUS2011178105
OPPOSITIONUS2011288171
OPPOSITIONWO2010147994
SEARCHEP2022495
SEARCHWO2010147994

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "DSM-IV) plus dysthymia", Diagnostic and Statistical Manual of Mental Disorders-
DESCRIPTION- MSR Lipid Analysis, Scottish Crop Research Institute-
DESCRIPTION- "Text Revision (''TR'') criteria", Mini International Neuropsychiatric Interview (''MINI'')/Diagnostic and Statistical Manual of Mental Disorders, WB Saunders Company-
OPPOSITION- Who, "Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus", WHO/NMH/CHP/CPM/11.1, (20110101), WHO/NMH/CHP/CPM/11.1 , URL: https://apps.who.int/iris/bitstream/handle/10665/70523/WHO_NMH_CHP_CPM_11.1_eng.pdf, (20220607), XP055928191-
OPPOSITION- H.A. KHAN, "Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients", Acta Diabetol, (20070000), vol. 44, doi:10.1007/s00592-007-0003-x, pages 193 - 200, XP019565057
OPPOSITION- Mcbride Patrick, "Triglycerides and risk for coronary artery disease", Current Atherosclerosis Reports, Springer US, New York, New York, (20081016), vol. 10, no. 5, doi:10.1007/s11883-008-0060-9, ISSN 1523-3804, pages 386 - 390, XP055928181
OPPOSITION- HAROLD E BAYS et al., "Etosapentaersote Acid Ethyl Ester (AMR101) Therapy In Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension (MARINE) Trial", AMERICAN JOURNAL OF CARDIOLOGY, NEWTON, MA, US, (20110424), vol. 108, no. 5, doi:10.1016/j.amjcard.2011.04.015, pages 682 - 690, XP028262633
OPPOSITION- Y. SAITO et al., "Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS", Atherosclerosis, (20080000), vol. 200, doi:10.1016/j.atherosclerosis.2008.06.003, pages 135 - 140, XP024521515
OPPOSITION- Barter Philip, "HDL-C: Role as a risk modifier", Atherosclerosis Supplements, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20111101), vol. 12, no. 3, doi:10.1016/S1567-5688(11)70885-6, ISSN 1567-5688, pages 267 - 270, XP055928176
OPPOSITION- Eeg-Olofsson K., Cederholm J., Nilsson P. M., Zethelius B., Svensson A.-M., Gudbjörnsdóttir S., Eliasson B., "New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR) : HbA1c and CVD in type 2 diabetes", JOURNAL OF INTERNAL MEDICINE, Blackwell Publishing Ltd, GB, GB , (20101101), vol. 268, no. 5, doi:10.1111/j.1365-2796.2010.02265.x, ISSN 0954-6820, pages 471 - 482, XP055928189
OPPOSITION- Rimei Nishimura;Tomoko Nakagami;Hirohito Sone;Yasuo Ohashi;Naoko Tajima, "Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial", Cardiovasc Diabetology, BIOMED CENTRAL, LONDON, GB, GB , (20110630), vol. 10, no. 1, doi:10.1186/1475-2840-10-58, ISSN 1475-2840, page 58, XP021105350
OPPOSITION- Eliot A Brinton;Christie M Ballantyne;Harold E Bays;John J Kastelein;Rene A Braeckman;Paresh N Soni, "Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR st", Cardiovasc Diabetology, BIOMED CENTRAL, LONDON, GB, GB , (20130709), vol. 12, no. 1, doi:10.1186/1475-2840-12-100, ISSN 1475-2840, page 100, XP021156640
OPPOSITION- NORIKO SATOH et al., "Purified eioosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein In metabolic syndrome", DIABETES CARE, vol. 30, no. 1, ISSN 0149-5992, (20070101), pages 144 - 146, URL: http;//care.diabetesjournals.org/content/30/1 144, XP002677407
SEARCH- BALLANTYNE CHRISTIE M ET AL, "AMR101 Lowers Triglycerides, Atherogenic Lipoprotein, Phospholipase A(2), and High-sensitivity C-reactive Protein Levels in Patients With High Triglycerides and on Background Statin Therapy (the ANCHOR Study)", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, (20111122), vol. 124, no. 21, Suppl, ISSN 0009-7322, XP009184942 [X] 10-15 * the whole document * [Y] 1-9-
SEARCH- HAROLD E BAYS ET AL, "Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)", AMERICAN JOURNAL OF CARDIOLOGY, CAHNERS PUBLISHING CO., NEWTON, MA, US, vol. 108, no. 5, doi:10.1016/J.AMJCARD.2011.04.015, ISSN 0002-9149, (20110424), pages 682 - 690, (20110530), XP028262633 [Y] 1-15 * see whole document; page 687, column 1, paragraph 2 * * page 688, column 1, lines 32-34 *
SEARCH- NORIKO SATOH ET AL, "Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome", vol. 30, no. 1, doi:10.2337/DC06-1179, ISSN 0149-5992, (20070101), pages 144 - 146, DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, URL: http://care.diabetesjournals.org/content/30/1/144, XP002677407 [X] 10-15 * the whole document * [Y] 1-9

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents